Ovarian
cancer is one of the most dreadful type of cancer widely found in
women. In this cancer, abnormal cells growth is experienced in the
ovaries, which has potential to invade or adversely affect other body
parts such as abdomen layers, lining of the bowel and bladder, lymph
nodes, and liver. Initial stages of ovarian cancer are associated
with few vague symptoms, which further manifest as the cancer grows.
These symptoms include inflating, pelvic ache, abdominal puffiness,
and loss of appetite.
Ovarian
cancer is a relatively rare cancer as compared to other types, though
risk is higher among women who have ovulated more over their
lifetime, which can also include females who have never borne a child
and those who began ovulating at a very young age. According to
American Cancer Society, around 10% of ovarian cancer cases are
related to inherited genetic risk. Women with mutations in BRCA1 or
BRCA2 genes have 50% chance of developing breast or ovarian cancer.
Ovarian carcinoma, is the most common ovarian cancer that accounts
for 95% of cases, globally.
Request
a Sample Copy @
https://www.coherentmarketinsights.com/insight/request-sample/164
Ovarian
cancer drugs market supported by growing aging population in the U.S.
and U.K.
Rising
number of ovarian cancer cases recorded over the recent past, is
creating a highly conducive environment for growth of the ovarian
cancer drugs market. According to American Cancer Society, in 2016,
around 22,280 new cases of ovarian cancer were diagnosed, leading to
14,240 deaths in the U.S. According to the Surveillance, Epidemiology
and End Results (SEER) Program of the National Cancer Institute data,
an increase in all new cancer cases is recorded, with ovarian cancer
accounting for 1.3% of the incidence rate, and 2.4% of all related
deaths, in 2016.
Current
scenario in ovarian cancer drugs market: High prevalence of ovarian
cancer among women over 60 years in the U.S. and U.K.
Regional
segmentation of the global ovarian cancer drugs market by Coherent
Market Insights comprises North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa. North America accounts for the
largest market share, mainly due to presence of major players and
adoption of advanced medical technologies in countries such as the
U.S. and Canada. According to American Cancer Society, an estimated
22,440 women would receive a new diagnosis of ovarian cancer and
around 14,080 women will die from ovarian cancer in 2017 in the U.S.
alone. Ovarian cancer is the fifth most prevalent cancer among women,
which accounts for high percentage of deaths when compared to other
cancer related to reproductive system cancer.
Combinational
drug approach, a novel approach in the ovarian cancer drugs market
Key
players operating in the ovarian cancer drugs market include Bristol
Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc,
Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera
Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche
Ltd.
Ovarian
Cancer Drugs Market Taxonomy
The
global ovarian cancer drugs market is segmented on the basis of
chemotherapy drugs, end user, and geography.
On
the basis of chemotherapy drugs, the ovarian cancer drugs are
segmented into:
-
Carboplatin
-
Cisplatin
-
Docetaxel
-
Paclitaxel
-
Other Medication (Cyclophosphamide, Doxorubicin, Gemcitabine, Oxaliplatin, and Topotecan).
For
More Information, Browse Complete Report Here:
https://www.coherentmarketinsights.com/ongoing-insight/ovarian-cancer-drugs-market-164
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment